GlassScriptPhysician profile
Michele Coulter
NPI 1780660522
$5,006.30
in general payments reported to CMS, 2019-2025
41 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $238 · 2021: $315 · 2022: $785 · 2023: $874 · 2024: $1,113 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,216.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $977.52 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Pfizer INC. | $682.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $394.09 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Lilly USA, LLC | $377.56 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Corium, LLC | $335.19 | 2023-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $189.01 | 2019-2025 | Airsupra, Flumist Quadrivalent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.07 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.30 | 2019-2024 | Jardiance |
| Axsome Therapeutics, INC. | $158.70 | 2024-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $143.37 | 2023-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Amgen INC. | $141.24 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $115.83 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $114.52 | 2019-2023 | |
| Astellas Pharma US INC | $107.64 | 2022-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $100.33 | 2022-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Coulter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.